📊 GEHC Key Takeaways
Is GE HealthCare Technologies Inc. (GEHC) a Good Investment?
While GEHC demonstrates 4.8% revenue growth in essential healthcare equipment markets, deteriorating profitability metrics signal operational distress. Flat net income despite revenue expansion, severely depressed returns on equity (3.6%) and assets (1.0%), combined with high leverage (0.95x D/E) and weak liquidity (0.95x quick ratio), indicate the company is struggling to convert growth into shareholder value and carries meaningful financial risk.
GE HealthCare shows solid core fundamentals with mid-single-digit revenue growth, healthy 40.0% gross margin, and double-digit operating and net margins. However, flat net income and negative free cash flow indicate weaker earnings-to-cash conversion, which tempers the quality of growth despite a manageable liquidity profile and acceptable leverage.
Why Buy GE HealthCare Technologies Inc. Stock? GEHC Key Strengths
- Stable 4.8% YoY revenue growth in essential medical imaging/healthcare equipment sector
- Operates in recurring revenue-generating healthcare technology market with structural demand
- Positive operating cash flow of $290M provides minimum debt service capability
- Healthy profitability profile with 40.0% gross margin, 13.4% operating margin, and 10.1% net margin
- Revenue and diluted EPS both grew 4.8% year over year, indicating continued operating resilience
- Balance sheet remains serviceable with 1.37x current ratio, 1.13x quick ratio, and strong 20.1% ROE
GEHC Stock Risks: GE HealthCare Technologies Inc. Investment Risks
- Critical margin compression: 4.8% revenue growth offset by 0.0% net income growth indicates operational deterioration
- Extremely poor capital efficiency: ROE of 3.6% and ROA of 1.0% far below cost of capital, destroying shareholder value
- Elevated financial risk: Debt/Equity of 0.95x with $10.1B long-term debt, weak quick ratio of 0.95x, and minimal cash ($2.3B) limit financial flexibility
- Weak free cash flow generation: $112M FCF on $5.1B revenue (2.2% margin) provides insufficient buffer for debt service or growth investment
- Operating cash flow of only $344M versus $2.08B net income suggests weak cash conversion
- Free cash flow was negative at -$138M, raising questions about underlying cash generation quality
- Leverage is meaningful with $10.00B long-term debt and debt-to-equity of 0.96x, limiting flexibility if cash flow stays soft
Key Metrics to Watch
- Net profit margin trend - critical to reverse compression and demonstrate operational improvement
- Free cash flow generation and FCF margin - must exceed capex needs and generate debt paydown
- Debt/Equity ratio and interest coverage ratio - assess debt sustainability and refinancing risk
- Return on Equity trajectory - currently unacceptable at 3.6%
- Operating cash flow and free cash flow recovery
- Net income growth relative to revenue growth
GE HealthCare Technologies Inc. (GEHC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 2.2% FCF margin may limit capital allocation flexibility.
GEHC Profit Margin, ROE & Profitability Analysis
GEHC vs Market Sector: How GE HealthCare Technologies Inc. Compares
How GE HealthCare Technologies Inc. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GE HealthCare Technologies Inc. Stock Overvalued? GEHC Valuation Analysis 2026
Based on fundamental analysis, GE HealthCare Technologies Inc. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GE HealthCare Technologies Inc. Balance Sheet: GEHC Debt, Cash & Liquidity
GEHC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GE HealthCare Technologies Inc.'s revenue has shown modest growth of 5% over the 5-year period. The most recent EPS of $3.03 reflects profitable operations.
GEHC Revenue Growth, EPS Growth & YoY Performance
GEHC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.8B | $389.0M | $0.85 |
| Q3 2025 | $4.9B | $446.0M | $0.98 |
| Q2 2025 | $4.8B | $428.0M | $0.93 |
| Q1 2025 | $4.7B | $374.0M | $0.81 |
| Q3 2024 | $4.8B | $375.0M | $0.82 |
| Q2 2024 | $4.8B | $418.0M | $0.91 |
| Q1 2024 | $4.7B | $372.0M | $0.41 |
| Q3 2023 | $4.6B | $375.0M | $0.82 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GE HealthCare Technologies Inc. Dividends, Buybacks & Capital Allocation
GEHC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GE HealthCare Technologies Inc. (CIK: 0001932393)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 7, 2026 | 4 | xslF345X06/wk-form4_1778184869.xml | View → |
| May 7, 2026 | 4 | xslF345X06/wk-form4_1778184524.xml | View → |
| May 1, 2026 | 4 | xslF345X06/wk-form4_1777649933.xml | View → |
| Apr 30, 2026 | 4 | xslF345X06/wk-form4_1777580461.xml | View → |
| Apr 30, 2026 | 4 | xslF345X06/wk-form4_1777580401.xml | View → |
❓ Frequently Asked Questions about GEHC
What is the AI rating for GEHC?
GE HealthCare Technologies Inc. (GEHC) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GEHC's key strengths?
Claude: Stable 4.8% YoY revenue growth in essential medical imaging/healthcare equipment sector. Operates in recurring revenue-generating healthcare technology market with structural demand. ChatGPT: Healthy profitability profile with 40.0% gross margin, 13.4% operating margin, and 10.1% net margin. Revenue and diluted EPS both grew 4.8% year over year, indicating continued operating resilience.
What are the risks of investing in GEHC?
Claude: Critical margin compression: 4.8% revenue growth offset by 0.0% net income growth indicates operational deterioration. Extremely poor capital efficiency: ROE of 3.6% and ROA of 1.0% far below cost of capital, destroying shareholder value. ChatGPT: Operating cash flow of only $344M versus $2.08B net income suggests weak cash conversion. Free cash flow was negative at -$138M, raising questions about underlying cash generation quality.
What is GEHC's revenue and growth?
GE HealthCare Technologies Inc. reported revenue of $5.1B.
Does GEHC pay dividends?
GE HealthCare Technologies Inc. pays dividends, with $16.0M distributed to shareholders in the trailing twelve months.
Where can I find GEHC SEC filings?
Official SEC filings for GE HealthCare Technologies Inc. (CIK: 0001932393) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GEHC's EPS?
GE HealthCare Technologies Inc. has a diluted EPS of $0.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GEHC a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, GE HealthCare Technologies Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GEHC stock overvalued or undervalued?
Valuation metrics for GEHC: ROE of 3.6% (sector avg: 15%), net margin of 7.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GEHC stock in 2026?
Our dual AI analysis gives GE HealthCare Technologies Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GEHC's free cash flow?
GE HealthCare Technologies Inc.'s operating cash flow is $290.0M, with capital expenditures of $178.0M. FCF margin is 2.2%.
How does GEHC compare to other Market stocks?
Vs Default sector averages: Net margin 7.6% (avg: 12%), ROE 3.6% (avg: 15%), current ratio 1.22 (avg: 1.8).